Endo Pharmaceuticals

299 articles with Endo Pharmaceuticals

• Endo Settles Opioid Investigation with State of Oklahoma for $8.75 million

  1/10/2020

  Endo International plc today announced that its subsidiaries Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc. have executed a Settlement Agreement with the State of Oklahoma.

• Football Legend John Elway Reveals He has Dupuytren's Contracture and Wants Others to Get the "Facts on Hand"

  8/22/2019

  Elway joins campaign aimed at encouraging those who think they may have Dupuytren's contracture to seek a diagnosis from a hand specialist and ask about treatments, including nonsurgical options

• Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray

  8/21/2019

  Annual market sales for the 12-months ending June 2019 were $90 million as measured by IQVIA™.

• 

  Teva to Pay California $69 Million in Pay-To-Delay Deal Settlement

  7/30/2019

  Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.

• Nationally Recognized Urologist and Author, Aaron Spitz, MD, Teams Up with Endo Pharmaceuticals' Ask About the Curve Campaign to Encourage Men to Get "In Touch" With Their Anatomy This Men's Health Month

  6/6/2019

  Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal.

• Perrigo Confirms Patent Challenge for Generic Version of Nascobal®

  3/5/2019

  This action formally initiates the litigation process under the Hatch-Waxman Act.

• Baron & Budd Secures $13.25 Million to Settle Texas Whistleblower Lawsuit Against Endo Pharmaceuticals for Fraudulently Marketing Lidoderm for Unapproved Uses

  8/1/2018

  Today, the national law firm of Baron & Budd announced that Endo Pharmaceuticals. (“Endo”) has agreed to pay $13.25 million to settle a whistleblower lawsuit brought by the State of Texas under the Texas Medicaid Fraud Prevention Act (“TMFPA”).

• Endo Announces Master Settlement Agreement Allowing for Resolution of Known Testosterone Replacement Therapy Product Liability Claims and Entry of Significant Case Management Order

  6/11/2018

  Endo International plc announced that its subsidiaries Endo Pharmaceuticals Inc. and Auxilium Pharmaceuticals, LLC have executed a definitive master settlement agreement allowing for the resolution of all known testosterone replacement therapy product liability claims against the Company.

• 

  Opioid Distributors on Congressional Hot Seat Over Addiction Crisis

  5/9/2018

  Sitting before a Congressional panel Tuesday the heads of pharmaceutical distributing companies said their mea culpas over not doing more to limit the flow of prescription opioids to certain parts of the country.
• 

  The Growing Legal Battles Against Opioid Manufacturers

  4/18/2018

  Utah’s Salt Lake County is the latest governing body to enter the legal battle against opioid manufacturers, distributors and prescribers. Governments are seeking financial restitution for the funds they have spent on battling addiction to prescription opioid medications.
• 

  Department of Justice Seeks Greater Role in Opioid Lawsuit Settlement

  4/5/2018

  As legal battles over opioid drugs slowly move through the courts the U.S. Department of Justice is adding its weight to the matter. This week the DOJ asked the courts for permission to help settle disputes brought by state and local governments against opioid manufacturers and distributors.
• 

  Sorrento Nabs FDA Approval for Shingles Pain Patch That Could Hit Blockbuster Status

  3/1/2018

  Sorrento Therapeutics, Inc. nabbed regulatory approval for ZTlido, a non-opioid pain treatment in the form of a super-sticky patch.

• Endo Announces Appointment of Dr. Sharad S. Mansukani to Board of Directors and Resignation of Mr. Douglas S. Ingram

  11/8/2017

  Ingram's decision to resign as a director from the Company's Board of Directors effective November 6, 2017 is due to his appointment as President and CEO of Sarepta Therapeutics earlier this year.

• Endo Pharma Caves To The FDA, Agrees To Yank Opana ER From Market

  7/7/2017

• First Time Ever: FDA Asks Endo Pharma to Stop Selling Opana ER Amid Opioid Crisis

  6/9/2017

• Endo Pharma Issues Voluntary Nationwide Recall For One Lot Of Edex (Alprostadil For Injection) 10 Mcg 2 Pack Carton Due To Potential Lack Of Sterility Assurance

  2/27/2017

• BioDelivery Closes Transaction To Reacquire License To BELBUCA From Endo Pharma

  1/9/2017

• BioDelivery Reacquires License To BELBUCA From Endo Pharma

  12/8/2016

• Endo Pharma Presents New Phase 2 Data Evaluating The Safety And Effectiveness Of XIAFLEX (Collagenase Clostridium Histolyticum) For Dupuytren's Disease Nodules

  9/30/2016

• Endo Pharma Announces FDA Advisory Committee Meeting For OPANA ER

  6/15/2016